MA32175B1 - Oxadiazoanthracènes pour le traitement du diabète - Google Patents

Oxadiazoanthracènes pour le traitement du diabète

Info

Publication number
MA32175B1
MA32175B1 MA33212A MA33212A MA32175B1 MA 32175 B1 MA32175 B1 MA 32175B1 MA 33212 A MA33212 A MA 33212A MA 33212 A MA33212 A MA 33212A MA 32175 B1 MA32175 B1 MA 32175B1
Authority
MA
Morocco
Prior art keywords
derivatives
diabetes
treatment
oxadiazo
oxadiazoanthracenes
Prior art date
Application number
MA33212A
Other languages
Arabic (ar)
English (en)
Inventor
Adnan M M Mjalli
Dharma Rao Polisetti
Thomas Scott Yokum
Kalpathy Santhosh
Mustafa Guzel
Christopher Behme
Stephen Thomas Davis
Original Assignee
Transtech Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transtech Pharma Inc filed Critical Transtech Pharma Inc
Publication of MA32175B1 publication Critical patent/MA32175B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des dérivés de l'oxadiazoanthracène de formule (i) dans laquelle a, b, c, r, r1, r2, r3, r4 et r5 sont tels que décrits dans la description, des compositions pharmaceutiques comprenant les dérivés de l'oxadiazoanthracène, l'utilisation des dérivés de l'oxadiazoanthracène pour la préparation de compositions pharmaceutiques, des procédés de leur utilisation pour le traitement et/ou la prévention de maladies et de troubles tels que le diabète et des intermédiaires utiles pour la préparation des dérivés de l'oxadiazoanthracène de formule (i).
MA33212A 2008-03-07 2010-09-30 Oxadiazoanthracènes pour le traitement du diabète MA32175B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3459908P 2008-03-07 2008-03-07
PCT/US2009/036333 WO2009111700A2 (fr) 2008-03-07 2009-03-06 Oxadiazoanthracènes pour le traitement du diabète

Publications (1)

Publication Number Publication Date
MA32175B1 true MA32175B1 (fr) 2011-03-01

Family

ID=41056666

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33212A MA32175B1 (fr) 2008-03-07 2010-09-30 Oxadiazoanthracènes pour le traitement du diabète

Country Status (17)

Country Link
US (7) US7727983B2 (fr)
EP (1) EP2262364B1 (fr)
JP (1) JP5382952B2 (fr)
KR (1) KR101616737B1 (fr)
CN (1) CN101959405B (fr)
AU (1) AU2009221722B2 (fr)
BR (1) BRPI0910282A2 (fr)
CA (1) CA2716664C (fr)
DK (1) DK2262364T3 (fr)
EA (1) EA018225B1 (fr)
ES (1) ES2567451T3 (fr)
IL (1) IL207570A (fr)
MA (1) MA32175B1 (fr)
MX (1) MX2010009752A (fr)
NZ (1) NZ587343A (fr)
WO (1) WO2009111700A2 (fr)
ZA (1) ZA201006367B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101616737B1 (ko) 2008-03-07 2016-05-02 브이티브이 테라퓨틱스 엘엘씨 당뇨병 치료를 위한 옥사디아조안트라센 화합물
CA2757084C (fr) * 2009-03-30 2017-08-29 Transtech Pharma, Inc. Derives d'azoanthracene substitues, compositions pharmaceutiques et leurs procedes d'utilisation
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
MX2013006768A (es) 2010-12-23 2013-07-22 Pfizer Moduladores de receptor de glucagon.
WO2012096824A1 (fr) 2011-01-12 2012-07-19 Transtech Pharma, Inc. Dérivés d'acide phénylglyoxylique et leur préparation et utilisation
ES2597972T3 (es) 2011-02-08 2017-01-24 Pfizer Inc Modulador del receptor de glucagón
RU2013157388A (ru) 2011-07-22 2015-08-27 Пфайзер Инк. Хинолинильные модуляторы глюкагонового рецептора
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013045413A1 (fr) 2011-09-27 2013-04-04 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b] pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
JP2015510947A (ja) 2012-03-22 2015-04-13 トランステック・ファーマ，エルエルシー 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
WO2014064215A1 (fr) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhibiteurs de la kinase tpl2 pour prévenir ou traiter le diabète et favoriser la survie de cellules β
WO2014113357A1 (fr) * 2013-01-17 2014-07-24 Transtech Pharma, Llc Combinaisons d'un agoniste du glp1r et de metformine, et leur utilisation pour le traitement du diabète de type 2 et d'autres troubles
US9474755B2 (en) * 2014-07-25 2016-10-25 Celgene International Ii Sarl GLP-1 receptor modulators
WO2016151018A1 (fr) 2015-03-24 2016-09-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthode et composition pharmaceutique destinées à être utilisées dans le traitement du diabète
JOP20190060A1 (ar) 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2019103060A1 (fr) * 2017-11-22 2019-05-31 第一三共株式会社 Composé tricyclique condensé
KR20260036616A (ko) 2018-05-08 2026-03-17 브이티브이 테라퓨틱스 엘엘씨 Glp1r 작용제의 치료적 용도
CU20210042A7 (es) 2018-11-22 2022-01-13 Qilu Regor Therapeutics Inc Compuestos agonistas de glp-1r y composiciones farmacéuticas que lo contienen
BR112021020335A2 (pt) * 2019-04-12 2021-12-14 Qilu Regor Therapeutics Inc Agonistas glp-1r e usos dos mesmos
PE20221040A1 (es) 2019-10-25 2022-06-17 Gilead Sciences Inc Compuestos moduladores de glp-1r
EP4141008A4 (fr) 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Sel d'acide pharmaceutiquement acceptable de base libre d'agoniste du récepteur glp-1, et son procédé de préparation
JP2023528565A (ja) 2020-04-01 2023-07-05 ハンジョウ ジョンメイ フアドン ファーマシューティカル シーオー．，エルティーディー． Ｇｌｐ－１受容体アゴニストの結晶形ａおよびその調製法
TW202144340A (zh) 2020-04-03 2021-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用
EP4159737A4 (fr) * 2020-05-28 2024-10-09 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Procédé de préparation d'une base libre d'agoniste du récepteur glp-1
EP4159719A4 (fr) * 2020-05-28 2024-07-17 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Procédé de préparation de sel de diacide de propanoate de méthyle (s)-2-amino-3-(4-(2,3-diméthylpyridine-4-yl)phényl)
CN119930605A (zh) 2020-09-01 2025-05-06 江苏恒瑞医药股份有限公司 稠合咪唑类衍生物、其制备方法及其在医药上的应用
CN116348464A (zh) 2020-10-12 2023-06-27 杭州中美华东制药有限公司 苯并咪唑酮类glp-1受体激动剂及其用途
WO2022078352A1 (fr) * 2020-10-14 2022-04-21 Qilu Regor Therapeutics Inc. Formes cristallines d'agonistes de glp-1 r et leurs utilisations
WO2022109182A1 (fr) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Composés modulateurs de glp-1r polyhétérocycliques
CA3200245A1 (fr) 2020-11-27 2022-06-02 Junjun Wu Derive de benzimidazole, son procede de preparation et son utilisation medicale
CN116940561A (zh) 2021-03-22 2023-10-24 杭州中美华东制药有限公司 噻吩类glp-1受体激动剂及其用途
JP7772778B2 (ja) 2021-03-24 2025-11-18 塩野義製薬株式会社 縮合環を有するｇｌｐ－１受容体作動薬を含有する医薬組成物
PL4271672T3 (pl) 2021-04-21 2026-04-20 Gilead Sciences, Inc. Karboksybenzimidazolowe związki modulujące glp-1r
CN117500808B (zh) * 2021-06-17 2026-03-06 杭州中美华东制药有限公司 蒽类化合物、其制备方法和医药用途
MX2023014985A (es) 2021-06-24 2024-02-14 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista del receptor de glp-1 y composicion y uso del mismo.
CN115521320B (zh) * 2021-06-25 2023-09-05 沈阳兴齐眼药股份有限公司 一种制备普拉洛芬的方法
EP4592285A1 (fr) 2022-09-22 2025-07-30 Shionogi & Co., Ltd. Composé à cycle condensé ayant un effet agoniste du récepteur glp-1
AU2024340407A1 (en) 2023-09-14 2026-04-23 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (fr) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Agoniste de glp-1r et son procédé thérapeutique
WO2025158275A1 (fr) 2024-01-24 2025-07-31 Pfizer Inc. Polythérapie utilisant des composés antagonistes du récepteur du polypeptide insulinotrope glucose-dépendant et des composés agonistes du récepteur glp-1
WO2025189141A1 (fr) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Méthodes de traitement de l'obésité et d'augmentation de la perte de poids

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6345270A (ja) * 1986-02-11 1988-02-26 Takeda Chem Ind Ltd １，４−ベンゾオキサジン誘導体，その製造法およびそれを含有する医薬用組成物
EP0233728A1 (fr) * 1986-02-11 1987-08-26 Takeda Chemical Industries, Ltd. Dérivés de 1,4-benzoxazine, leur préparation et leur application
BR9610875A (pt) * 1995-10-06 1999-07-13 Ligand Pharm Inc Modulares rxr seletivos - dimeros e processos para seu uso
JP2002534512A (ja) * 1999-01-15 2002-10-15 ノボ ノルディスク アクティーゼルスカブ 非ペプチドｇｌｐ−１アゴニスト
CZ20021911A3 (cs) * 1999-12-03 2002-10-16 Kyoto Pharmaceutical Industries, Ltd. Nové heterocyklické sloučeniny a jejich soli a jejich vyuľití v lékařství
EP1125925A1 (fr) 2000-02-15 2001-08-22 Applied Research Systems ARS Holding N.V. Dérivés amines pour le traitement de l'apoptose
US20050222036A1 (en) * 2000-08-24 2005-10-06 Thomas Jefferson University Peptide compositions with effects on blood glucose
AU2004224156B2 (en) * 2003-03-26 2010-08-12 Actelion Pharmaceuticals Ltd. Tetrahydroisoquinolyl acetamide derivatives for use as orexin receptor antagonists
KR101616737B1 (ko) * 2008-03-07 2016-05-02 브이티브이 테라퓨틱스 엘엘씨 당뇨병 치료를 위한 옥사디아조안트라센 화합물
JP2013530963A (ja) 2010-06-09 2013-08-01 レセプトス インコーポレイテッド 新規のｇｌｐ−１受容体安定化薬および調節薬

Also Published As

Publication number Publication date
CN101959405A (zh) 2011-01-26
US20100197677A1 (en) 2010-08-05
DK2262364T3 (en) 2016-03-21
US8703766B2 (en) 2014-04-22
AU2009221722B2 (en) 2014-12-18
IL207570A0 (en) 2010-12-30
EA201071045A1 (ru) 2011-02-28
US20090306063A1 (en) 2009-12-10
US7790714B2 (en) 2010-09-07
AU2009221722A1 (en) 2009-09-11
US8933222B2 (en) 2015-01-13
JP5382952B2 (ja) 2014-01-08
ZA201006367B (en) 2011-05-25
US7906507B2 (en) 2011-03-15
US20140187769A1 (en) 2014-07-03
JP2011513431A (ja) 2011-04-28
CA2716664A1 (fr) 2009-09-11
EA018225B1 (ru) 2013-06-28
US7727983B2 (en) 2010-06-01
NZ587343A (en) 2012-05-25
CN101959405B (zh) 2014-07-02
US20130317015A1 (en) 2013-11-28
KR20100131455A (ko) 2010-12-15
MX2010009752A (es) 2010-09-30
WO2009111700A2 (fr) 2009-09-11
KR101616737B1 (ko) 2016-05-02
EP2262364A4 (fr) 2012-04-04
EP2262364B1 (fr) 2016-03-02
IL207570A (en) 2014-03-31
US8524708B2 (en) 2013-09-03
ES2567451T3 (es) 2016-04-22
US20110039837A1 (en) 2011-02-17
CA2716664C (fr) 2016-10-11
WO2009111700A3 (fr) 2010-03-04
US20100324033A1 (en) 2010-12-23
US20150087640A1 (en) 2015-03-26
HK1148435A1 (en) 2011-09-09
EP2262364A2 (fr) 2010-12-22
US9120813B2 (en) 2015-09-01
BRPI0910282A2 (pt) 2015-09-01

Similar Documents

Publication Publication Date Title
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
CL2011002115A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
MA34916B1 (fr) Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201491060A1 (ru) Новые производные трифторметилоксадиазола и их применение для лечения заболевания
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
EA201200794A1 (ru) Триазолопиридины
EA201200918A1 (ru) Производные пирролидин карбоновой кислоты как агонисты сопряженного с g-белком рецептора 43 (gpr43), фармацевтическая композиция и методы их использования при лечении метаболических нарушений
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
TW200621777A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
TW200621262A (en) New dihydropteridione derivatives, process for their manufacture and their use as medicament
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA201270492A1 (ru) Соединения для лечения дислипидемии и связанных с ней заболеваний
MX2011006006A (es) Compuestos, composicion farmaceutica y metodos para utilizarse en el tratamiento de trastornos metabolicos.
NO20090979L (no) (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX342924B (es) Nuevos compuestos disustituidos de 3,4-diamino-3-ciclobuteno-1,2-d iona para uso en el tratamiento de patologias mediadas por quimiocinas.